Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares gained 18% to $16.63. The company on Mar. 17 announced that data highlighting the potential pharmacoeconomic benefit of Zerenex(TM) (ferric citrate coordination complex), the Company’s drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy’s (AMCP) 26th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Center in Tampa, Florida. Keryx Biopharmaceuticals (NASDAQ:KERX) shares after opening at $14.20 moved to $17.29, on last trade day and at the end of the day closed at $16.54. Company price to sales ratio in past twelve months was calculated as 194.80 and price to cash ratio as 24.48. Keryx Biopharmaceuticals (NASDAQ:KERX) showed a positive weekly performance of 8.60%.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced that it will report financial results for the fourth quarter and full year ended December 31, 2013, after the market close on Thursday, March 27, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, March 27, 2014, to discuss the financial results and provide a corporate update. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares advanced 6.23% in last trading session and ended the day on $10.06. CNAT return on equity ratio is recorded as 18.10% and its return on assets is -26.40%.
Fate Therapeutics Inc (NASDAQ:FATE) released fourth quarter earnings. Overall, shares gained 6.15% following the fourth quarter results. Fate Therapeutics Inc (NASDAQ:FATE) shares moved up 11.64% in last trading session and was closed at $12.28, while trading in range of $11.18 – 13.55. Fate Therapeutics Inc (NASDAQ:FATE) year to date (YTD) performance is 95.54%.
China Biologic Products, Inc. (NASDAQ:CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, announced that the Company has received the Good Manufacturing Practice (“GMP”) certification from China Food and Drug Administration (“CFDA”) in respect of its plasma production facility at its Guizhou subsidiary. China Biologic Products Inc (NASDAQ:CBPO) weekly performance is -2.67%. On last trading day company shares ended up $35.04. China Biologic Products Inc (NASDAQ:CBPO) distance from 50-day simple moving average (SMA50) is 8.75%. Analysts mean target price for the company is $46.00.